Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Miyamoto, S, Duncan, G E, Marx, C E, Lieberman, J A·2005·Molecular Psychiatry
DOI 10.1038/sj.mp.4001556

Cites (393)

Items 201–390 of 390

  1. Schizophrenia and L-745, 870, a novel dopamine D4 receptor antagonist
    Linda J. Bristow, Mark S. Kramer, Janusz J. Kulagowski, Smita S. Patel, C. Ian RAGAN, Guy R. Seabrook · 1997 · Trends in Pharmacological Sciences
  2. Muscarinic Receptors as a Target for Drugs Treating Schizophrenia
    Frank P. Bymaster, Christian C. Felder, Saeed Ahmed, David L. McKinzie · 2002 · CNS & Neurological Disorders - Drug Targets
  3. Another view of therapy for cognition in schizophrenia.
    W. Carpenter, J. Gold · 2002 · Biological Psychiatry
  4. Current and Novel Approaches to the Drug Treatment of Schizophrenia
    Michael Rowley, Linda J. Bristow, Peter H. Hutson · 2001 · Journal of Medicinal Chemistry
  5. Cognitive Function in Schizophrenia— Do Neuroleptics Make a Difference?
    Ann Margaret Mortimer · 1997 · Pharmacology Biochemistry and Behavior
  6. Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells
    Natalio Vita, Florence Oury-Donat, Pascale Chalon, Marie Guillemot, Mourad Kaghad, André Bachy, Olivier Thurneyssen, Stephanie García, Caroline Poinot‐Chazel, Pierre Casellas et al. · 1998 · European Journal of Pharmacology
  7. The relationship between D 2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study
    Shitij Kapur, Robert B. Zipursky, Paul Roy, Corey Jones, Gary J. Remington, Ken L. Reed, Sylvain Houle · 1997 · Psychopharmacology
  8. Effects of Risperidone in Tardive Dyskinesia: An Analysis of the Canadian Multicenter Risperidone Study*
    Guy Chouinard · 1995 · Journal of Clinical Psychopharmacology
  9. Binding of Antipsychotic Drugs to Cortical 5-HT2A Receptors: A PET Study of Chlorpromazine, Clozapine, and Amisulpride in Schizophrenic Patients
    Christian Trichard, Marie‐Laure Paillère Martinot, Dominique Attar-Levy, Christophe Recasens, François P. Monnet, Jean‐Luc Martinot · 1998 · American Journal of Psychiatry
  10. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation
    Gary E. Duncan, Jeremy N. Leipzig, Richard B. Mailman, Jeffery A. Lieberman · 1998 · Brain Research
  11. Dehydroepiandrosterone sulfate attenuates dizocilpine-induced learning impairment in mice via σ1-receptors
    Tangui Maurice, Jean‐Louis Junien, Alain Privat · 1997 · Behavioural Brain Research
  12. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism
    Johanna K. Simosky, Karen E. Stevens, Lawrence E. Adler, Robert Freedman · 2003 · Psychopharmacology
  13. S33084, a Novel, Potent, Selective, and Competitive Antagonist at Dopamine D3-Receptors: II. Functional and Behavioral Profile Compared with GR218,231 and L741,626
    Mark John Millan, Anne Dekeyne, Jean‐Michel Rivet, Thierry Dubuffet, Gilbert Lavielle, Mauricette Brocco · 2000 · Journal of Pharmacology and Experimental Therapeutics
  14. Facilitative Effects of the Ampakine CX516 on Short-Term Memory in Rats: Correlations with Hippocampal Neuronal Activity
    Robert E. Hampson, Gary A. Rogers, GARY S. LYNCH, Sam A. Deadwyler · 1998 · Journal of Neuroscience
  15. Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors
    Adrian Newman‐Tancredi, Christine Chaput, Laurence Verrièle, Mark John Millan · 1996 · Neuropharmacology
  16. Guanfacine treatment of cognitive impairment in schizophrenia
    Friedman, J · 2001 · Neuropsychopharmacology
  17. Potentiation by dehydroepiandrosterone of the neuronal response to N-methyl-D-aspartate in the CA3 region of the rat dorsal hippocampus: an effect mediated via sigma receptors.
    Guy Debonnel, Richard Bergeron, Claude de Montigny · 1996 · PubMed
  18. Is Regionally Selective D2/D3 Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [123I]Epidepride SPET Study of Amisulpride-Treated Patients
    Rodrigo A. Bressan, Kjell Erlandsson, HUGH M. JONES, Rachel S. Mulligan, Robert James Flanagan, Peter Josef Ell, Lyn S. Pilowsky · 2003 · American Journal of Psychiatry
  19. Understanding the Mechanism of Action of Atypical Antipsychotic Drugs: A Review of Compounds in Use and Development
    Lieberman, Jeffrey A. · 1993 · British Journal of Psychiatry
  20. Allosteric Modulation of Nicotinic Receptors as a Treatment Strategy for Alzheimer’s Disease
    Alfred Maelicke · 2000 · Dementia and Geriatric Cognitive Disorders
  21. Intragastric DMXB-A, an α7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice
    Johanna K. Simosky, Karen E. Stevens, William R. Kem, Robert Freedman · 2001 · Biological Psychiatry
  22. 8-OH-DPAT, a 5-HT 1A agonist and ritanserin, a 5-HT 2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release
    Guillaume Lucas, Norbert Bonhomme, Philippe De Deurwaerdère, Michel Le Moal, Umberto Spampinato · 1997 · Psychopharmacology
  23. Neuropsychologic Deficits in Schizophrenia Relation to Social Function and Effect of Antipsychotic Drug Treatment
    H.Y. Meltzer · 1996 · Neuropsychopharmacology
  24. The current status of neuroleptic therapy.
    John Michael Kane · 1989 · PubMed
  25. Neuroprotection by dehydroepiandrosteronesulfate
    Xianrong R. Mao, Steven W. Barger · 1998 · Neuroreport
  26. Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses
    Johannes Thome, Peter Foley, Peter Franz Riederer · 1998 · Journal of Neural Transmission
  27. Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and11C-raclopride
    C.J. Bench, Adriaan A. Lammertsma, Raymond J. Dolan, Paul M. Grasby, SJ Warrington, K. P. Gunn, M. Cuddigan, D. J. Turton, S. Osman, Richard S. J. Frackowiak · 1993 · Psychopharmacology
  28. Review of atypical antipsychotics and weight gain.
    N Sussman · 2001 · PubMed
  29. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia
    Robert W. Buchanan, Ann T. Summerfelt, Cenk Tek, James M. Gold · 2002 · Schizophrenia Research
  30. Cognitive improvement during Tolcapone treatment in Parkinson's disease
    Maurizio Gasparini, E. Fabrizio, Vincenzo Bonifati, Giuseppe Meco · 1997 · Journal of Neural Transmission
  31. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs
    Elisabeth B. Binder, Becky L. Kinkead, Michael J. Owens, Charles B. Nemeroff · 2001 · Biological Psychiatry
  32. Clozapine: is another view valid?
    Herbert Y. Meltzer · 1995 · American Journal of Psychiatry
  33. In Vivo Extrastriatal and Striatal D2 Dopamine Receptor Blockade by Amisulpride in Schizophrenia
    X. Xiberas, Jean‐Luc Martinot, Luc Mallet, Eric Artiges A, Muriel Canal, Christian Loc’h, Bernard Maziere, Marie‐Laure Paillère Martinot · 2001 · Journal of Clinical Psychopharmacology
  34. Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia
    Johan A. den Boer, Harold J.G.M. van Megen, Bernhard R. Slaap, Herman G.M. Westenberg, W. Wolfgang Fleischhacker, J. W. Louwerens, G D Burrows, O. N. Srivastava · 1995 · Psychopharmacology
  35. Placebo-Controlled Study of the D4/5-HT2A Antagonist Fananserin in the Treatment of Schizophrenia
    Philippe Truffinet, Carol A. Tamminga, Louis F. Fabre, Herbert Y. Meltzer, Marie-Emmanuelle Riviï¿ ⁄ re, Catherine Papillon-Downey · 1999 · American Journal of Psychiatry
  36. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain
    Jun’ichi Semba, A. Watanabe, S. Kito, Michio Toru · 1995 · Neuropharmacology
  37. Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue: a [3H]NGD-94-1 study
    Robert A. Lahti, Rosalinda C. Roberts, Erika V. Cochrane, Renee J. Primus, Dorothy W. Gallager, Robert R. Conley, Carol A. Tamminga · 1998 · Molecular Psychiatry
  38. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.
    Kalpana Merchant, G.S. Gill, David W. Harris, Rita M. Huff, Misty J. Eaton, K.J. Lookingland, Barry S. Lutzke, Robert B. McCall, Montford F. Piercey, Peggy J. K. D. Schreur et al. · 1996 · Journal of Pharmacology and Experimental Therapeutics
  39. Comparison of the Effects of Clozapine, Risperidone, and Olanzapine on Ketamine-Induced Alterations in Regional Brain Metabolism
    Gary E. Duncan, Seiya Miyamoto, Jeremy N. Leipzig, Jeffrey Alan Lieberman · 2000 · Journal of Pharmacology and Experimental Therapeutics
  40. D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.
    Gary Remington, Shitij Kapur · 1999 · PubMed
  41. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia
    G E Duncan, Samuel J. Zorn, Jeffrey Alan Lieberman · 1999 · Molecular Psychiatry
  42. Understanding antipsychotic “atypicality”: a clinical and pharmacological moving target
    Gary J. Remington · 2003 · Journal of Psychiatry and Neuroscience
  43. The effects of neurosteroids on acquisition and retention of a modified passive-avoidance learning task in mice
    Doodipala Samba Reddy, S.K. Kulkarni · 1998 · Brain Research
  44. The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK801
    David L. Willins, Shridhar Narayanan, Lane J. Wallace, Norman J. Uretsky · 1993 · Pharmacology Biochemistry and Behavior
  45. Clonidine improves memory function in schizophrenia independently from change in psychosis. Preliminary findings
    Fields, R.B., Van Kammen, D.P., Peters, J.L., Rosen, J., Van Kammen, W.B., Nugent, A., Stipetic, M., Linnoila, M. · 1988 · Schizophrenia Research
  46. Selective Antagonism at Dopamine D3 Receptors Enhances Monoaminergic and Cholinergic Neurotransmission in the Rat Anterior Cingulate Cortex
    Laurent P. Lacroix, Mark E. P. Hows, Ajit J. Shah, Jim J. Hagan, Christian A. Heidbreder · 2002 · Neuropsychopharmacology
  47. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics
    Frank I. Tarazi, Wouter J. Florijn, Ian Creese · 1996 · Psychopharmacology
  48. Quetiapine
    Vikram Dev, J. Raniwalla · 2000 · Drug Safety
  49. Metabotropic Glutamate Receptors: Potential Drug Targets for the Treatment of Schizophrenia
    Laura E. Chavez-Noriega, Hervé Schaffhauser, Una C. Campbell · 2002 · CNS & Neurological Disorders - Drug Targets
  50. Synergistic Interactions between Ampakines and Antipsychotic Drugs
    Steven A. Johnson, Nguyen T. Luu, Todd Herbst, Richard J. Knapp, David Lutz, Amy Arai, Gary A. Rogers, GARY S. LYNCH · 1999 · Journal of Pharmacology and Experimental Therapeutics
  51. Novel Antipsychotic-Like Effects on Prepulse Inhibition of Startle Produced by a Neurotensin Agonist
    David Feifel, Tammi L. Reza, David J. Wustrow, Michael Duff Davis · 1999 · Journal of Pharmacology and Experimental Therapeutics
  52. Dopamine Receptor Subtypes: Differential Regulation after 8 Months Treatment with Antipsychotic Drugs
    Wouter J. Florijn, Frank I. Tarazi, Ian Creese · 1997 · Journal of Pharmacology and Experimental Therapeutics
  53. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia
    Jean‐Luc Martinot, M.H. Dao-Castellana, Christian Loc’h, Bernard Maziere, M F Poirier, Marie‐Laure Paillère Martinot · 1996 · Psychopharmacology
  54. Effects of α4/β2- and α7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice
    Rudy Schreiber, M. Dalmus, Jean De Vry · 2001 · Psychopharmacology
  55. The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography
    C.J. Bench, Adriaan A. Lammertsma, Paul M. Grasby, Raymond J. Dolan, Richard S. J. Frackowiak, SJ Warrington, Malcolm J. Boyce, K. P. Gunn, L. Y. Brannick · 1996 · Psychopharmacology
  56. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors
    Simon Fleminger, Nadia M.J. Rupniak, M.D. Hall, Peter G. Jenner, C. DAVID MARSDEN · 1983 · Biochemical Pharmacology
  57. Selective dopamine D 4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition
    Robert S. Mansbach, Elizabeth Brooks, Stevin H. Zorn, Mark A. Sanner · 1998 · Psychopharmacology
  58. Long-Term Effects of Olanzapine, Risperidone, and Quetiapine on Ionotropic Glutamate Receptor Types: Implications for Antipsychotic Drug Treatment
    Frank I. Tarazi, Ross J. Baldessarini, Nora S. Kula, Kehong Zhang · 2003 · Journal of Pharmacology and Experimental Therapeutics
  59. Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function
    Richard Alonso, Brigitte Voutsinos‐Porche, Marie Fournier, Christophe Labie, Régis Steinberg, Josiane Souilhac, Gérard Le Fur, P. Soubrié · 1999 · Neuroscience
  60. Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural effects on prepulse inhibition and locomotor activity in the rat
    Curt Johansson, David M. Jackson, Lennart Svensson · 1997 · Psychopharmacology
  61. Antipsychotic drug treatment induces differential gene expression in the rat cortex
    Outi Kontkanen, Petri Törönen, Merja Lakso, Garry Wong, Eero Ċastrén · 2002 · Journal of Neurochemistry
  62. Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys
    Jay S. Schneider, Zuoli Sun, David P. Roeltgen · 1994 · Brain Research
  63. Nicotinic Agonists and Psychosis
    Johanna K. Simosky, Karen E. Stevens, Robert Freedman · 2002 · CNS & Neurological Disorders - Drug Targets
  64. Aripiprazole: A New Atypical Antipsychotic Drug
    Toya M. Bowles, Gary M. Levin · 2003 · Annals of Pharmacotherapy
  65. Adjuvant Galantamine Administration Improves Negative Symptoms in a Patient With Treatment-Refractory Schizophrenia
    Richard B. Rosse, Stephen I. Deutsch · 2002 · Clinical Neuropharmacology
  66. Reversal of Phencyclidine-Induced Hyperactivity by Glycine and the Glycine Uptake Inhibitor Glycyldodecylamide
    Daniel C. Javitt · 1997 · Neuropsychopharmacology
  67. Clozapine, But Not Haloperidol, Prevents the Functional Hyperactivity of N-Methyl-d-Aspartate Receptors in Rat Cortical Neurons Induced by Subchronic Administration of Phencyclidine
    Victor L. Arvanov, R.Y. Wang · 1999 · Journal of Pharmacology and Experimental Therapeutics
  68. Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs
    Marco Andrea Riva, Fabio Tascedda, E. Lovati, Giorgio Racagni · 1997 · Molecular Brain Research
  69. The Role of Dopamine D4 Receptor in the Induction of Behavioral Sensitization to Amphetamine and Accompanying Biochemical and Molecular Adaptations
    Dawna L. Feldpausch, Lana M. Needham, Michael P. Stone, John S. Althaus, Bryan K. Yamamoto, Kjell A. Svensson, Kalpana Merchant · 1998 · Journal of Pharmacology and Experimental Therapeutics
  70. Modulation of Nicotinic Receptor Activity in the Central Nervous System
    Edson Xavier Albuquerque, Máriton D. Santos, Manickavasagom Alkondon, Edna F. R. Pereira, Alfred Maelicke · 2001 · Alzheimer Disease & Associated Disorders
  71. Broad therapeutic uses of atypical antipsychotic medications
    P.F. Buckley · 2001 · Biological Psychiatry
  72. Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications
    Michael Foster Green, DAVID L. BRAFF · 2001 · Biological Psychiatry
  73. Pre-clinical Pharmacology of Atypical Antipsychotic Drugs: A Selective Review
    Herbert Y. Meltzer · 1996 · The British Journal of Psychiatry
  74. Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse
    Daniel C. Javitt, Mark J. Frusciante · 1997 · Psychopharmacology
  75. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours
    John P.M. Finberg, Moussa B. H. Youdim · 2002 · Neuropharmacology
  76. Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties
    H.‐J. Möller · 1993 · European Neuropsychopharmacology
  77. Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series
    Stefano Marenco, Michael F. Egan, Terry E. Goldberg, Michael B. Knable, Robert K. McClure, Georg Winterer, Daniel R. Weinberger · 2002 · Schizophrenia Research
  78. Catechol 0-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats
    R. Liljequist, Antti Haapalinna, Maria Ahlander, Ying Hua Li, Pekka T. Männistö · 1997 · Behavioural Brain Research
  79. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
    Dawn I. Velligan, Alexander L. Miller · 1999 · PubMed
  80. [Glutamatergic hypothesis of schizophrenia].
    R. Bressan, L. Pilowsky · 2003 · Revista Brasileira de Psiquiatria
  81. Calcineurin and intracellular Ca2+-release channels: regulation or association?
    Geert Bultynck, Elke Vermassen, Karolina Szlufcik, Patrick De Smet, Rafael A. Fissore, Geert Callewaert, Ludwig Missiaen, Humbert DE SMEDT, Jan B. Parys · 2003 · Biochemical and Biophysical Research Communications
  82. COMT inhibitors and liver toxicity.
    Paul Brent Watkins · 2000 · PubMed
  83. Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain
    Andrea Schmitt, Mathias Zink, Georg A. Petroianu, Brigitte May, Dieter F. Braus, Fritz A. Henn · 2003 · Neuroscience Letters
  84. Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils
    M. Poncelet, M.C. Barnouin, Jean-Claude Brelière, Gérard Le Fur, Philippe Soubrié · 1999 · Psychopharmacology
  85. M100907 and Clozapine, but not Haloperidol or Raclopride, Prevent Phencyclidine-Induced Blockade of NMDA Responses in Pyramidal Neurons of the Rat Medial Prefrontal Cortical Slice
    R Wang, Ph.D. · 1998 · Neuropsychopharmacology
  86. Negative Symptoms in Schizophrenia: Neurobiological Models and Treatment Response
    DONALD C. GOFF, Anne Eden Evins · 1998 · Harvard Review of Psychiatry
  87. The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents
    George Kenneth Lloyd, Frédérique Menzaghi, Bruno Bontempi, Carla M. Suto, R. Siegel, MICHAEL AKONG, Kenneth A. Stauderman, Gönül Veliçelebi, Edwin C. Johnson, Michael M. Harpold et al. · 1998 · Life Sciences
  88. Mechanism of Peripheral Noradrenergic Stimulation by Clozapine
    Igor Elman · 1999 · Neuropsychopharmacology
  89. Neurosteroids Ameliorate Conditioned Fear Stress An Association with Sigma1 Receptors
    Yukihiro Noda · 2000 · Neuropsychopharmacology
  90. 7-Nitroindazole and Methylene Blue, Inhibitors of Neuronal Nitric Oxide Synthase and NO-Stimulated Guanylate Cyclase, Block MK-801-Elicited Behaviors in Mice
    Stephen I. Deutsch · 1996 · Neuropsychopharmacology
  91. Methylene Blue Adjuvant Therapy of Schizophrenia
    Stephen I. Deutsch, Richard B. Rosse, Barbara L. Schwartz, Maureen Fay-McCarthy, Paul B. Rosenberg, Kim B. Jones-Fearing · 1997 · Clinical Neuropharmacology
  92. Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone.
    Alan J. Fischman, Ali A. Bonab, John W. Babich, Nathaniel M. Alpert, Scott L. Rauch, David R. Elmaleh, Timothy M. Shoup, S A Williams, Robert H. Rubin · 1996 · Journal of Pharmacology and Experimental Therapeutics
  93. Comparison of the Binding Activities of Some Drugs on α 2A , α 2B and α 2C ‐Adrenoceptors and Non‐Adrenergic Imidazoline Sites in the Guinea Pig
    Uhlén, Staffan, Muceniece, Ruta, Rangel, Ninfa, Tiger, Gunnar, Wikberg, Jarl E. S. · 1995 · Pharmacology & Toxicology
  94. Effects of Long-Term Antipsychotic Treatment on NMDA Receptor Binding and Gene Expression of Subunits
    Andrea Schmitt, Mathias Zink, Bettina Müller, Brigitte May, Anne Herb, Alexander Jatzko, Dieter F. Braus, Fritz A. Henn · 2003 · Neurochemical Research
  95. Galantamine for Treatment-Resistant Schizophrenia
    Trina B. Allen, Joseph P. McEvoy · 2002 · American Journal of Psychiatry
  96. Towards the improvement of compliance
    Wolfgang Gäebel · 1997 · International Clinical Psychopharmacology
  97. Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum
    Daniel J. Healy, James H. Meador‐Woodruff · 1997 · Molecular Brain Research
  98. SIB-1553A, (±)-4-{[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio}phenol Hydrochloride, a Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors with Putative Cognitive-Enhancing Properties: Effects on Working and Reference Memory Performances in Aged Rodents and Nonhuman Primates
    Bruno Bontempi, Kevin T. Whelan, Victoria B. Risbrough, Tadimeti S. Rao, Jerry J. Buccafusco, George Kenneth Lloyd, Frédérique Menzaghi · 2001 · Journal of Pharmacology and Experimental Therapeutics
  99. Negative symptoms: diagnosis, treatment and prognosis
    Robert W. Buchanan, James M. Gold · 1996 · International Clinical Psychopharmacology
  100. The American Psychiatric Press Textbook of Psychopharmacology
    David L. Dünner · 1995 · American Journal of Psychiatry
  101. Deconstructing Schizophrenia
    Constance Holden · 2003 · Science
  102. Effects of σ1 receptor agonist SA4503 and neuroactive steroids on performance in a radial arm maze task in rats
    Li-Bo Zou, Kiyofumi Yamada, Masashi Sasa, Yoshihiro Nakata, Toshitaka NABESHIMA · 2000 · Neuropharmacology
  103. Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.
    Émmanuel Stip · 2000 · PubMed
  104. Treatment of Negative Symptoms in Schizophrenia and Schizoaffective Disorder by Selegiline Augmentation of Antipsychotic Medication
    J. Alexander Bodkin, Bruce M. Cohen, Melinda S. Salomon, SOPHIE E. CANNON, Gwen L. Zornberg, Jonathan O Cole · 1996 · The Journal of Nervous and Mental Disease
  105. Erratum Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597): A Study Using Positron Emission Tomography and [11C]Raclopride
    2002 · Neuropsychopharmacology
  106. 8,9-Dihydroxy-2,3,7,11b-tetrahydro-1 H -naph[1,2,3- de ]isoquinoline: A Potent Full Dopamine D 1 Agonist Containing a Rigid β-Phenyldopamine Pharmacophore
    Debasis Ghosh, Scott E. Snyder, Val J. Watts, Richard B. Mailman, David E. Nichols · 1996 · Journal of Medicinal Chemistry
  107. NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia
    Jesper Karle, Henrik Lublin, Jes Gerlach, Lars Clemmesen, L. Hansen, Mikkel Østerheden Andersen, J. Andersen, Conni Fensbo, Mogens Sloth-Nielsen, Birte K. Skrumsager · 1995 · Psychopharmacology
  108. Schizophrenia (2nd edn). Edited by Steven R. Hirsch & Daniel R. Weinberger Oxford: Blackwell. 2003. 768 pp. £89.50 (hb). ISBN 0 632063882
    A. M. Denman · 2004 · The British Journal of Psychiatry
  109. Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats
    Fabio Tascedda, Joan M.C Blom, Nicoletta Brunello, Katia Zolin, Massimo Gennarelli, Anna Colzi, Daniele Bravi, Serena Carra, Giorgio Racagni, Marco Andrea Riva · 2001 · Biological Psychiatry
  110. Neurotensin: an endogenous antipsychotic?
    Becky L. Kinkead · 2002 · Current Opinion in Pharmacology
  111. Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin 1A receptors
    Ariel R. Ase, Fatima Amdiss, Caroline Hébert, Ning Huang, N. M. van Gelder, Tomás A. Reader · 1999 · Journal of Neural Transmission
  112. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine
    Wolfgang Hauber, Ragna Andersen · 1993 · Naunyn-Schmiedeberg s Archives of Pharmacology
  113. Nitric Oxide Synthase Inhibitors Attenuate Phencyclidine-Induced Disruption of Prepulse Inhibition
    Jenny L. Wiley · 1998 · Neuropsychopharmacology
  114. Involvement of nitric oxide in phencyclidine-induced hyperlocomotion in mice
    Yukihiro Noda, Kiyofumi Yamada, Hiroshi Furukawa, Toshitaka NABESHIMA · 1995 · European Journal of Pharmacology
  115. Schizophrenia and L-745, 870, a novel dopamine D4 receptor antagonist
    Linda J. Bristow, Mark S. Kramer, Janusz J. Kulagowski · 1997 · Trends in Pharmacological Sciences
  116. In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs
    Valeria Bigliani, Rachel S. Mulligan, Paul D. Acton, Dimitris Visvikis, Peter Josef Ell, Caroline Stephenson, Robert W Kerwin, Lyn S. Pilowsky · 1999 · The British Journal of Psychiatry
  117. Blunted brain metabolic response to ketamine in mice lacking D1A dopamine receptors
    Seiya Miyamoto, Richard B. Mailman, Jeffrey Alan Lieberman, Gary E. Duncan · 2001 · Brain Research
  118. Regulation of Ionotropic Glutamate Receptors in the Rat Brain in Response to the Atypical Antipsychotic Seroquel (Quetiapine Fumarate)
    Fabio Tascedda · 1999 · Neuropsychopharmacology
  119. Differential regulation of hippocampal AMPA and kainate receptor subunit expression by haloperidol and clozapine.
    James H. Meador‐Woodruff, R E King, Scott P. Damask, Bovenkerk Ka · 1996 · PubMed
  120. Striatal Extracellular Dopamine Levels in Rats with Haloperidol-Induced Depolarization Block of Substantia Nigra Dopamine Neurons
    Holly M Moore, Christopher L. Todd, Anthony A. Grace · 1998 · Journal of Neuroscience
  121. Tolcapone-Related Liver Dysfunction
    Nuno Borges · 2003 · Drug Safety
  122. The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition
    Paul D. Shilling, Elliott Richelson, David Feifel · 2003 · Behavioural Brain Research
  123. The effect of chronic haloperidol treatment on glutamate receptor subunit (GluR1, GluR2, KA1, KA2, NR1) mRNAs and glutamate binding protein mRNA in rat forebrain
    Sharon L. Eastwood, Richard H.P. Porter, Paul J. Harrison · 1996 · Neuroscience Letters
  124. DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex
    James W. Sharp, D.L. Petersen, M.T. Langford · 1995 · Brain Research
  125. Behavioral Evidence of Depolarization Block of Dopamine Neurons after Chronic Treatment with Haloperidol and Clozapine
    Sandra M. Boye, Pierre-Paul Rompré · 2000 · Journal of Neuroscience
  126. Biological Perspectives
    Norman L. Keltner, Vicki Johnson · 2002 · Perspectives In Psychiatric Care
  127. Current Issues in the Psychopharmacology of Schizophrenia
    Ho Kwan Cheung · 2002 · Hong Kong journal of psychiatry
  128. New drugs for the treatment of schizophrenic patients
    W. Wolfgang Fleischhacker · 1995 · Acta Psychiatrica Scandinavica
  129. Schizophrenia and mood disorders : the new drug therapies in clinical practice
    P.F. Buckley, John L. Waddington · 1999
  130. Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats
    Krystyna Ossowska, Malgorzata Pietraszek, Jadwiga Wardas, Gabriel Nowak, Stanisław Wolfarth · 1999 · Naunyn-Schmiedeberg s Archives of Pharmacology
  131. Dehydroisoandrosterone in Psychiatric Treatment
    Eric Benjamin Strauss, Dalton E. Sands, A. M. Robinson, W. J. Tindall, Wilf Stevenson · 1952 · BMJ
  132. Depolarization inactivation of dopamine neurons: an artifact?
    Giampaolo Mereu, Vanessa Lilliu, Pierfrancesco Vargiu, Al Muntoni, Marco Diana, G. L. Gessa · 1995 · Journal of Neuroscience
  133. The role of glutamate receptors in antipsychotic drug action
    Krystyna Ossowska, Malgorzata Pietraszek, Jadwiga Wardas, Gabriel Nowak, W. Zajaczkowski, S. Wolfarth, Andrzej Pilc · 2000 · Amino Acids
  134. Facilitated NMDA receptor-mediated synaptic plasticity in the hippocampal CA1 area of dystrophin-deficient mice
    Cyrille Vaillend, Arielle Ungerer, Jean‐Marie Billard · 1999 · Synapse
  135. Further Studies on Endocrine Treatment in Adolescence and Early Adult Life
    Dalton E. Sands · 1954 · Journal of Mental Science
  136. Atypical antipsychotic drugs improve cognition in schizophrenia
    Herbert Y. Meltzer, Tomiki Sumiyoshi · 2003 · Biological Psychiatry
  137. Repeated Administration of the Neurotensin Receptor Antagonist SR 48692 Differentially Regulates Mesocortical and Mesolimbic Dopaminergic Systems
    Mounia Azzi, Catalina Betancur, Inge Sillaber, Rainer Spanagel, William H. Rostène, Anne Bérod · 1998 · Journal of Neurochemistry
  138. Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase
    Makoto Naoi, W. Maruyama, Moussa B. H. Youdim, P. H. Yu, Alan A. Boulton · 2003 · Inflammopharmacology
  139. Dr. Goff Replies
    DONALD C. GOFF · 1995 · American Journal of Psychiatry
  140. Donepezil in schizophrenia — is it helpful? An experimental design case study
    G. William MacEwan, Tom S. Ehmann, I. Khanbhai, C. Wrixon · 2001 · Acta Psychiatrica Scandinavica
  141. Chronic treatment with haloperidol diminishes the phencyclidine-induced sensorimotor gating deficit in rats
    Malgorzata Pietraszek, Krystyna Ossowska · 1998 · Naunyn-Schmiedeberg s Archives of Pharmacology
  142. Temporal variations in androgens and stress hormones in control and schizophrenic subjects.
    Garfield Tourney, Judith L. Erb · 1979 · PubMed
  143. Nicotine increases stress-induced serotonin release by stimulating nicotinic acetylcholine receptor in rat striatum
    Hiroshi Takahashi, Yumiko Takada, Nobuo Nagai, Tetsumei Urano, Akikazu Takada · 1998 · Synapse
  144. Clozapine: a comparison with other novel antipsychotics.
    W. Wolfgang Fleischhacker · 1999 · PubMed
  145. Chronic Administration of Haloperidol and Olanzapine Attenuates Ketamine-Induced Brain Metabolic Activation
    Gary E. Duncan, Seiya Miyamoto, Jeffrey Alan Lieberman · 2003 · Journal of Pharmacology and Experimental Therapeutics
  146. Long-term effects of neuroleptic drugs on the neuroendocrine system.
    Meltzer Hy · 1985 · PubMed
  147. The new and evolving pharmacotherapy of schizophrenia
    Robin Alexander Emsley, Piet P. Oosthuizen · 2003 · Psychiatric Clinics of North America
  148. Clozapine response varies in deficit vs non-deficit schizophrenic subjects
    Robert R. Conley, Charles M. Richardson, Dawn Kent, Cathy Gounaris, Sandra Zaremba · 1994 · Biological Psychiatry
  149. Non-equipotent doses partly explain differences among antipsychotics - implications of PET studies
    S. Nyberg, Lars Farde · 2000 · Psychopharmacology
  150. Effect of chronic clozapine administration on [3H]MK801-binding sites in the rat brain: a side-preference action in cortical areas
    Luciana Giardino, Francesca Bortolotti, Catello Orazzo, Monica Pozza, Palmiero Monteleone, Laura Calzà, Mario Maj · 1997 · Brain Research
  151. Deprenyl Augmentation for Treating Negative Symptoms of Schizophrenia: A Double-Blind, Controlled Study
    Tal Jungerman, David L. Rabinowitz, Ehud Klein · 1999 · Journal of Clinical Psychopharmacology
  152. Developing novel antipsychotic drugs: Strategies and goals
    Seiya Miyamoto, G E Duncan, Richard B. Mailman, Jeffrey A. Lieberman · 2000
  153. Assessing the effects of atypical antipsychotics on negative symptoms
    Herbert Y. Meltzer · 1998 · The Journal of Clinical Psychiatry
  154. Effects of modulation of nitric oxide on acoustic startle responding and prepulse inhibition in rats
    Jenny L. Wiley, Keith M. Golden, Scott E. Bowen · 1997 · European Journal of Pharmacology
  155. Failure of chronic haloperidol to induce depolarization inactivation of dopamine neurons in unanesthetized rats
    Giampaolo Mereu, Vanessa Lilliu, Pierfrancesco Vargiu, Anna Lisa Muntoni, Marco Diana, Gian Luigi Gessa · 1994 · European Journal of Pharmacology
  156. The Relevance of the Dopamine-D1 Receptor in the Cognitive Symptoms of Schizophrenia
    P. Goldman-Rakic · 1999 · Neuropsychopharmacology
  157. Haloperidol does not produce dopamine cell depolarization-block in paralyzed, unanesthetized rats
    Miriam Melis, Giampaolo Mereu, Vanessa Lilliu, Marina Quartu, Marco Diana, Gian Luigi Gessa · 1998 · Brain Research
  158. Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients
    Giovanni Umberto Corsini, Ubaldo Bonuccelli, Ernst Rainer, Maria Del Zompo · 1985 · Journal of Neural Transmission
  159. Evaluating the effects of antipsychotics on cognition in schizophrenia
    Herbert Y. Meltzer · 1998 · The Journal of Clinical Psychiatry
  160. New Developments in the pharmacotherapy of schizophrenia
    Wolfgang W. Fleischhacker · 2003 · Journal of neural transmission. Supplementum
  161. Schizophrenia: A genetic perspective (Review)
    Barkur S. Shastry · 2002 · International Journal of Molecular Medicine
  162. Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907
    Jeffrey M. Witkin, Maciej Ga̧sior, Jane B. Acri, Marjolein Beekman, Andrew Thurkauf, Jun Jie Yuan, Peter DeBoer, Håkan Wikström, Durk Dijkstra · 1998 · European Journal of Pharmacology
  163. Further Evidence that Behavioral Tests and Neuropeptide mRNA and Tissue Level Alterations Can Differentiate between Typical and Atypical Antipsychotic Drugs
    Richard Bauer · 2000 · Neuropsychopharmacology
  164. Neuroactive steroids: new biomarkers of cognitive aging
    Monique Vallée, Robert H. Purdy, Willy Mayo, George F. Koob, Michel Le Moal · 2003 · The Journal of Steroid Biochemistry and Molecular Biology
  165. Common treatment goals of antipsychotics: acute treatment.
    Zafar A. Sharif · 1998 · PubMed
  166. Chronic treatments with zotepine, thioridazine, and haloperidol affect apomorphine-elicited stereotypic behavior and striatal 3H-spiroperidol binding sites in the rat
    H. Lai, M.A. Carino, A. Horita · 1981 · Psychopharmacology
  167. Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain
    Frank I. Tarazi, Kehong Zhang, Ross J. Baldessarini · 2000 · Neuroscience Letters
  168. Donepezil for memory dysfunction in schizophrenia
    Andrew K. Howard, Allen E. Thornton, Siemion Altman, William G. Honer · 2002 · Journal of Psychopharmacology
  169. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
    Mark John Millan, A Gobert, Adrian Newman‐Tancredi, Françoise Lejeune, Didier Cussac, Jean‐Michel Rivet, Valérie Audinot, Agnès Adhumeau-Auclair, Mauricette Brocco, Jean‐Paul Nicolas et al. · 2000 · PubMed
  170. Effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) after repeated administration on a conditioned avoidance response (CAR) in the rat
    J. L. Evenden · 1992 · Psychopharmacology
  171. L-Deprenyl in treating negative symptoms of schizophrenia
    András Perényi, Utpal Goswami, Ede Frecska, Mihály Arató, Árpád Béla · 1992 · Psychiatry Research
  172. USE OF DEHYDROISOANDROSTERONE IN PSYCHIATRIC PRACTICE
    Eric Benjamin Strauss, Wilf Stevenson · 1955 · Journal of Neurology Neurosurgery & Psychiatry
  173. PRE- AND POSTSYNAPTIC D1 TO D5 DOPAMINE RECEPTOR MECHANISMS IN RELATION TO ANTIPSYCHOTIC ACTIVITY
    John L. Waddington · 1993 · Elsevier eBooks
  174. Osanetant Sanofi-Synthélabo.
    Farhad Kamali · 2001 · PubMed
  175. Pharmacological Manipulation of D1-Dopamine Receptor Function in Schizophrenia
    Göran Sedvall · 1999 · Neuropsychopharmacology
  176. Advances in the pharmacogenetic prediction of antipsychotic response
    Maria Jesús Arranz, Robert W Kerwin · 2003 · Toxicology
  177. Assessment of the serotonin reuptake blocking property of YM992: Electrophysiological studies in the rat hippocampus and dorsal raphe
    Jianming Dong, Claude de Montigny, Pierre Blier · 1999 · Synapse
  178. Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia
    Sanjay Gupta, Thomas Droney, Alan Kyser, Peggy Keller · 1999 · Comprehensive Psychiatry
  179. Psychiatry, 2nd Edn
    Debra A. Wood · 2005 · Australian & New Zealand Journal of Psychiatry
  180. Acute Pharmacological Treatment of Schizophrenia
    Seiya Miyamoto, T. Scott Stroup, G E Duncan, Anri Aoba, Jeffrey A. Lieberman · 2003
  181. Atypical antipsychotic-like effect of AMPA receptor antagonists in the rat
    Torgny H. Svensson, Jan M. Mathé · 2000 · Amino Acids
  182. Chronic treatments with haloperidol and clozapine alter the level of NMDA-R1 mRNA in the rat brain: an in situ hybridization study.
    Krystyna Ossowska, Malgorzata Pietraszek, Jadwiga Wardas, Marta Dziedzicka‐Wasylewska, Dorota Nowicka, Stanisław Wolfarth · 2002 · PubMed
  183. Improvement of Cognitive Dysfunction After Treatment With Second-Generation Antipsychotics
    Elisabeth M. Weiss, Georg Kemmler, W. Wolfgang Fleischhacker · 2002 · Archives of General Psychiatry
  184. Risperidone versus haloperidol for prevention of relapse in schizophrenia and schizoaffective disorders: Long-term double-blind comparison
    John C. Csernansky, Akiko Okamoto · 2000 · Schizophrenia Research
  185. When Neurotrophic Factors Get on Your Nerves: Therapy for Neurodegenerative Disorders
    Stephen M. Stahl · 1998 · The Journal of Clinical Psychiatry
  186. Aripiprazole: Does Partial Dopaminergic Agonism Translate into Clinical Benefits?
    M. Lynn Crismon, Anthony DeLeon, Alexander L. Miller · 2003 · Annals of Pharmacotherapy
  187. S.01.01 Antipsychotic effect of four different compounds — results of the metatrial
    Werner Rein, Lisa A. Arvanitis · 2003 · European Neuropsychopharmacology
  188. The neurochemical and behavioral effects of papaverine in vivo suggest PDE10 inhibition is “antipsychotic”
    C.J. Schmidt, Douglas S. Chapin, Sheryl A. McCarthy, RemieA. Fujiwara, John F. Harms, Alka Shrikhande, Leslie K. Chambers, S. Wong, Judith A. Siuciak · 2003 · Schizophrenia Research
  189. The Neuroscience and Clinical Psychopharmacology of First‐ and Second‐Generation Antipsychotic Drugs
    John L. Waddington, S. Kapur, Gary J. Remington · 2003
  190. Untitled work
    2002 · 10.1002/1439-7633(20021004)3:10